Cargando…

The CDC SHIELD Orange County Project – Baseline Multi Drug-Resistant Organism (MDRO) Prevalence in a Southern California Region

BACKGROUND: MDROs can spread between hospitals, nursing homes (NH), and long-term acute care facilities (LTACs) via shared patients. SHIELD OC is a regional decolonization collaborative involving 38 of 104 countywide adult facilities identified by their high degree of direct and indirect patient sha...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Raveena D, Jernigan, John A, Slayton, Rachel B, Stone, Nimalie D, McKinnell, James A, Miller, Loren G, Kleinman, Ken, Heim, Lauren, Dutciuc, Tabitha D, Estevez, Marlene, Gussin, Gabrielle, Chang, Justin, Peterson, Ellena M, Evans, Kaye D, Lee, Bruce Y, Mueller, Leslie E, Bartsch, Sarah M, Zahn, Matthew, Janssen, Lynn, Weinstein, Robert A, Hayden, Mary K, Gohil, Shruti K, Park, Steven, Tam, Steven, Saavedra, Raheeb, Yamaguchi, Stacey, Custodio, Harold, Nguyen, Jenny, Tjoa, Thomas, He, Jiayi, O’Donnell, Kathleen, Coady, Micaela H, Platt, Richard, Huang, Susan S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631751/
http://dx.doi.org/10.1093/ofid/ofx162.109
_version_ 1783269549742751744
author Singh, Raveena D
Jernigan, John A
Slayton, Rachel B
Stone, Nimalie D
McKinnell, James A
Miller, Loren G
Kleinman, Ken
Heim, Lauren
Dutciuc, Tabitha D
Estevez, Marlene
Gussin, Gabrielle
Chang, Justin
Peterson, Ellena M
Evans, Kaye D
Lee, Bruce Y
Mueller, Leslie E
Bartsch, Sarah M
Zahn, Matthew
Janssen, Lynn
Weinstein, Robert A
Hayden, Mary K
Gohil, Shruti K
Park, Steven
Tam, Steven
Saavedra, Raheeb
Yamaguchi, Stacey
Custodio, Harold
Nguyen, Jenny
Tjoa, Thomas
He, Jiayi
O’Donnell, Kathleen
Coady, Micaela H
Platt, Richard
Huang, Susan S
author_facet Singh, Raveena D
Jernigan, John A
Slayton, Rachel B
Stone, Nimalie D
McKinnell, James A
Miller, Loren G
Kleinman, Ken
Heim, Lauren
Dutciuc, Tabitha D
Estevez, Marlene
Gussin, Gabrielle
Chang, Justin
Peterson, Ellena M
Evans, Kaye D
Lee, Bruce Y
Mueller, Leslie E
Bartsch, Sarah M
Zahn, Matthew
Janssen, Lynn
Weinstein, Robert A
Hayden, Mary K
Gohil, Shruti K
Park, Steven
Tam, Steven
Saavedra, Raheeb
Yamaguchi, Stacey
Custodio, Harold
Nguyen, Jenny
Tjoa, Thomas
He, Jiayi
O’Donnell, Kathleen
Coady, Micaela H
Platt, Richard
Huang, Susan S
author_sort Singh, Raveena D
collection PubMed
description BACKGROUND: MDROs can spread between hospitals, nursing homes (NH), and long-term acute care facilities (LTACs) via shared patients. SHIELD OC is a regional decolonization collaborative involving 38 of 104 countywide adult facilities identified by their high degree of direct and indirect patient sharing with one another. We report baseline MDRO prevalence in these facilities. METHODS: Adult patients in 38 facilities (17 hospitals, 18 NHs, 3 LTACs) underwent point-prevalence screening between September 2016–April 2017 for MRSA, VRE, ESBL, and CRE using nares, skin (axilla/groin), and peri-rectal swabs. In NHs and LTACs, residents were randomly selected until 50 sets of swabs were obtained. Swabbing in hospitals involved all patients in contact precautions. An additional set of swabs were also performed for all LTAC admissions from November 2016–February 2017. RESULTS: The overall prevalence of any MDRO among patients was 64% (44%–88%) in NHs, 80% (range 72%–86%) in LTACs, and 64% (54–84%) in hospitals (contact precaution patients) (Table 1). Only 25%, 64%, and 81% of patients were already known to harbor an MDRO in NHs, LTACs, and hospitals, respectively. Known MDRO patients also harbored another MDRO 49%, 63%, and 34% of the time for NHs, LTACs, and hospitals, respectively. In LTACs, MDRO point prevalence was 38% higher than the usual admission prevalence (65% higher for MRSA, 34% higher for VRE, 95% higher for ESBL, and 50% higher for CRE). CONCLUSION: MDRO carriage in highly inter-connected NHs and LTACs was widespread, rivaling that found in hospitalized patients on contact precautions. MRSA, VRE, and ESBL carriage far outnumbered CRE carriage. A history of MDRO was insensitive for identifying MDRO carriers, and many patients carried multiple MDROs. The extensive MDRO burden and transmission in long-term care settings suggests that regional MDRO prevention efforts must include MDRO control in long-term care facilities. DISCLOSURES: R. D. Singh, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; 3M: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; J. A. McKinnell, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; 3M: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; L. G. Miller, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; 3M: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; K. Kleinman, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Molnlycke: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; 3M: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; L. Heim, Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; 3M: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; T. D. Dutciuc, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; 3M: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; M. Estevez, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; 3M: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; G. Gussin, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; L’Oreal: Consultant, Consulting fee; J. Chang, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; 3M: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; E. M. Peterson, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; B. Y. Lee, GSK: Consultant, Consulting fee; R. A. Weinstein, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Molnlycke: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; OpGen Company: Study support, Provided services at no charge; M. K. Hayden, Sage Products: Receipt of contributed product, Sage is contributing product to healthcare facilities participating in a regional collaborative on which I am a co-investigator. Neither I nor my hospital receive product.; Clorox: Receipt of contributed product, Research support; CDC: Grant Investigator and Receipt of contributed product, Research grant; Molnlycke: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; OpGen Company: Study support, Provided services at no charge for studies; S. K. Gohil, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; S. Park, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; S. Tam, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; 3M: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; R. Saavedra, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; S. Yamaguchi, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; H. Custodio, Xttrium Laboratories: Study coordination, Conducting studies in healthcare facilities that are receiving contributed product; Sage Products: Study coordination, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Study coordination, Conducting studies in healthcare facilities that are receiving contributed product; J. Nguyen, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; T. Tjoa, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; 3M: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; J. He, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; 3M: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; M. H. Coady, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Molnlycke: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; R. Platt, Sage Products: Receipt of contributed product, Conducting clinical studies in which participating healthcare facilities are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting clinical studies in which participating healthcare facilities are receiving contributed product; Clorox: Receipt of contributed product, Conducting clinical studies in which participating healthcare facilities are receiving contributed product; receive research funds from Clorox, but Clorox has no role in the design; Molnlycke: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; S. S. Huang, Sage Products: Receipt of contributed product, Conducting studies in which participating healthcare facilities are receiving contributed product (no contribution in submitted abstract), Participating healthcare facilities in my studies received contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in which participating healthcare facilities are receiving contributed product (no contribution in submitted abstract), Participating healthcare facilities in my studies received contributed product; Clorox: Receipt of contributed product, Conducting studies in which participating healthcare facilities are receiving contributed product (no contribution in submitted abstract), Participating healthcare facilities in my studies received contributed product; 3M: Receipt of contributed product, Conducting studies in which participating healthcare facilities are receiving contributed product (no contribution in submitted abstract), Participating healthcare facilities in my studies received contributed product; Molnlycke: Receipt of contributed product, Conducting studies in which participating healthcare facilities are receiving contributed product (no contribution in submitted abstract), Participating healthcare facilities in my studies received contributed product
format Online
Article
Text
id pubmed-5631751
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-56317512017-11-07 The CDC SHIELD Orange County Project – Baseline Multi Drug-Resistant Organism (MDRO) Prevalence in a Southern California Region Singh, Raveena D Jernigan, John A Slayton, Rachel B Stone, Nimalie D McKinnell, James A Miller, Loren G Kleinman, Ken Heim, Lauren Dutciuc, Tabitha D Estevez, Marlene Gussin, Gabrielle Chang, Justin Peterson, Ellena M Evans, Kaye D Lee, Bruce Y Mueller, Leslie E Bartsch, Sarah M Zahn, Matthew Janssen, Lynn Weinstein, Robert A Hayden, Mary K Gohil, Shruti K Park, Steven Tam, Steven Saavedra, Raheeb Yamaguchi, Stacey Custodio, Harold Nguyen, Jenny Tjoa, Thomas He, Jiayi O’Donnell, Kathleen Coady, Micaela H Platt, Richard Huang, Susan S Open Forum Infect Dis Abstracts BACKGROUND: MDROs can spread between hospitals, nursing homes (NH), and long-term acute care facilities (LTACs) via shared patients. SHIELD OC is a regional decolonization collaborative involving 38 of 104 countywide adult facilities identified by their high degree of direct and indirect patient sharing with one another. We report baseline MDRO prevalence in these facilities. METHODS: Adult patients in 38 facilities (17 hospitals, 18 NHs, 3 LTACs) underwent point-prevalence screening between September 2016–April 2017 for MRSA, VRE, ESBL, and CRE using nares, skin (axilla/groin), and peri-rectal swabs. In NHs and LTACs, residents were randomly selected until 50 sets of swabs were obtained. Swabbing in hospitals involved all patients in contact precautions. An additional set of swabs were also performed for all LTAC admissions from November 2016–February 2017. RESULTS: The overall prevalence of any MDRO among patients was 64% (44%–88%) in NHs, 80% (range 72%–86%) in LTACs, and 64% (54–84%) in hospitals (contact precaution patients) (Table 1). Only 25%, 64%, and 81% of patients were already known to harbor an MDRO in NHs, LTACs, and hospitals, respectively. Known MDRO patients also harbored another MDRO 49%, 63%, and 34% of the time for NHs, LTACs, and hospitals, respectively. In LTACs, MDRO point prevalence was 38% higher than the usual admission prevalence (65% higher for MRSA, 34% higher for VRE, 95% higher for ESBL, and 50% higher for CRE). CONCLUSION: MDRO carriage in highly inter-connected NHs and LTACs was widespread, rivaling that found in hospitalized patients on contact precautions. MRSA, VRE, and ESBL carriage far outnumbered CRE carriage. A history of MDRO was insensitive for identifying MDRO carriers, and many patients carried multiple MDROs. The extensive MDRO burden and transmission in long-term care settings suggests that regional MDRO prevention efforts must include MDRO control in long-term care facilities. DISCLOSURES: R. D. Singh, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; 3M: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; J. A. McKinnell, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; 3M: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; L. G. Miller, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; 3M: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; K. Kleinman, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Molnlycke: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; 3M: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; L. Heim, Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; 3M: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; T. D. Dutciuc, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; 3M: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; M. Estevez, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; 3M: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; G. Gussin, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; L’Oreal: Consultant, Consulting fee; J. Chang, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; 3M: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; E. M. Peterson, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; B. Y. Lee, GSK: Consultant, Consulting fee; R. A. Weinstein, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Molnlycke: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; OpGen Company: Study support, Provided services at no charge; M. K. Hayden, Sage Products: Receipt of contributed product, Sage is contributing product to healthcare facilities participating in a regional collaborative on which I am a co-investigator. Neither I nor my hospital receive product.; Clorox: Receipt of contributed product, Research support; CDC: Grant Investigator and Receipt of contributed product, Research grant; Molnlycke: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; OpGen Company: Study support, Provided services at no charge for studies; S. K. Gohil, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; S. Park, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; S. Tam, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; 3M: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; R. Saavedra, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; S. Yamaguchi, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; H. Custodio, Xttrium Laboratories: Study coordination, Conducting studies in healthcare facilities that are receiving contributed product; Sage Products: Study coordination, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Study coordination, Conducting studies in healthcare facilities that are receiving contributed product; J. Nguyen, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; T. Tjoa, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; 3M: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; J. He, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; 3M: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; M. H. Coady, Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Molnlycke: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; R. Platt, Sage Products: Receipt of contributed product, Conducting clinical studies in which participating healthcare facilities are receiving contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting clinical studies in which participating healthcare facilities are receiving contributed product; Clorox: Receipt of contributed product, Conducting clinical studies in which participating healthcare facilities are receiving contributed product; receive research funds from Clorox, but Clorox has no role in the design; Molnlycke: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; S. S. Huang, Sage Products: Receipt of contributed product, Conducting studies in which participating healthcare facilities are receiving contributed product (no contribution in submitted abstract), Participating healthcare facilities in my studies received contributed product; Xttrium Laboratories: Receipt of contributed product, Conducting studies in which participating healthcare facilities are receiving contributed product (no contribution in submitted abstract), Participating healthcare facilities in my studies received contributed product; Clorox: Receipt of contributed product, Conducting studies in which participating healthcare facilities are receiving contributed product (no contribution in submitted abstract), Participating healthcare facilities in my studies received contributed product; 3M: Receipt of contributed product, Conducting studies in which participating healthcare facilities are receiving contributed product (no contribution in submitted abstract), Participating healthcare facilities in my studies received contributed product; Molnlycke: Receipt of contributed product, Conducting studies in which participating healthcare facilities are receiving contributed product (no contribution in submitted abstract), Participating healthcare facilities in my studies received contributed product Oxford University Press 2017-10-04 /pmc/articles/PMC5631751/ http://dx.doi.org/10.1093/ofid/ofx162.109 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Singh, Raveena D
Jernigan, John A
Slayton, Rachel B
Stone, Nimalie D
McKinnell, James A
Miller, Loren G
Kleinman, Ken
Heim, Lauren
Dutciuc, Tabitha D
Estevez, Marlene
Gussin, Gabrielle
Chang, Justin
Peterson, Ellena M
Evans, Kaye D
Lee, Bruce Y
Mueller, Leslie E
Bartsch, Sarah M
Zahn, Matthew
Janssen, Lynn
Weinstein, Robert A
Hayden, Mary K
Gohil, Shruti K
Park, Steven
Tam, Steven
Saavedra, Raheeb
Yamaguchi, Stacey
Custodio, Harold
Nguyen, Jenny
Tjoa, Thomas
He, Jiayi
O’Donnell, Kathleen
Coady, Micaela H
Platt, Richard
Huang, Susan S
The CDC SHIELD Orange County Project – Baseline Multi Drug-Resistant Organism (MDRO) Prevalence in a Southern California Region
title The CDC SHIELD Orange County Project – Baseline Multi Drug-Resistant Organism (MDRO) Prevalence in a Southern California Region
title_full The CDC SHIELD Orange County Project – Baseline Multi Drug-Resistant Organism (MDRO) Prevalence in a Southern California Region
title_fullStr The CDC SHIELD Orange County Project – Baseline Multi Drug-Resistant Organism (MDRO) Prevalence in a Southern California Region
title_full_unstemmed The CDC SHIELD Orange County Project – Baseline Multi Drug-Resistant Organism (MDRO) Prevalence in a Southern California Region
title_short The CDC SHIELD Orange County Project – Baseline Multi Drug-Resistant Organism (MDRO) Prevalence in a Southern California Region
title_sort cdc shield orange county project – baseline multi drug-resistant organism (mdro) prevalence in a southern california region
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631751/
http://dx.doi.org/10.1093/ofid/ofx162.109
work_keys_str_mv AT singhraveenad thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT jerniganjohna thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT slaytonrachelb thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT stonenimalied thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT mckinnelljamesa thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT millerloreng thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT kleinmanken thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT heimlauren thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT dutciuctabithad thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT estevezmarlene thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT gussingabrielle thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT changjustin thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT petersonellenam thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT evanskayed thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT leebrucey thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT muellerlesliee thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT bartschsarahm thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT zahnmatthew thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT janssenlynn thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT weinsteinroberta thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT haydenmaryk thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT gohilshrutik thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT parksteven thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT tamsteven thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT saavedraraheeb thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT yamaguchistacey thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT custodioharold thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT nguyenjenny thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT tjoathomas thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT hejiayi thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT odonnellkathleen thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT coadymicaelah thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT plattrichard thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT huangsusans thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT thecdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT singhraveenad cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT jerniganjohna cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT slaytonrachelb cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT stonenimalied cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT mckinnelljamesa cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT millerloreng cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT kleinmanken cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT heimlauren cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT dutciuctabithad cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT estevezmarlene cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT gussingabrielle cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT changjustin cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT petersonellenam cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT evanskayed cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT leebrucey cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT muellerlesliee cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT bartschsarahm cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT zahnmatthew cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT janssenlynn cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT weinsteinroberta cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT haydenmaryk cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT gohilshrutik cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT parksteven cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT tamsteven cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT saavedraraheeb cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT yamaguchistacey cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT custodioharold cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT nguyenjenny cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT tjoathomas cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT hejiayi cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT odonnellkathleen cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT coadymicaelah cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT plattrichard cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT huangsusans cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion
AT cdcshieldorangecountyprojectbaselinemultidrugresistantorganismmdroprevalenceinasoutherncaliforniaregion